JP2019532996A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532996A5
JP2019532996A5 JP2019523626A JP2019523626A JP2019532996A5 JP 2019532996 A5 JP2019532996 A5 JP 2019532996A5 JP 2019523626 A JP2019523626 A JP 2019523626A JP 2019523626 A JP2019523626 A JP 2019523626A JP 2019532996 A5 JP2019532996 A5 JP 2019532996A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
terminus
subject
domain
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019523626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/060534 external-priority patent/WO2018089420A1/en
Publication of JP2019532996A publication Critical patent/JP2019532996A/ja
Publication of JP2019532996A5 publication Critical patent/JP2019532996A5/ja
Priority to JP2022080574A priority Critical patent/JP2022119829A/ja
Pending legal-status Critical Current

Links

JP2019523626A 2016-11-08 2017-11-08 自己免疫疾患を処置するためのｉｌ−２変異体 Pending JP2019532996A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022080574A JP2022119829A (ja) 2016-11-08 2022-05-17 自己免疫疾患を処置するためのｉｌ－２変異体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419118P 2016-11-08 2016-11-08
US62/419,118 2016-11-08
PCT/US2017/060534 WO2018089420A1 (en) 2016-11-08 2017-11-08 Il-2 variants for the treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022080574A Division JP2022119829A (ja) 2016-11-08 2022-05-17 自己免疫疾患を処置するためのｉｌ－２変異体

Publications (2)

Publication Number Publication Date
JP2019532996A JP2019532996A (ja) 2019-11-14
JP2019532996A5 true JP2019532996A5 (https=) 2020-11-12

Family

ID=62065637

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523626A Pending JP2019532996A (ja) 2016-11-08 2017-11-08 自己免疫疾患を処置するためのｉｌ−２変異体
JP2022080574A Pending JP2022119829A (ja) 2016-11-08 2022-05-17 自己免疫疾患を処置するためのｉｌ－２変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022080574A Pending JP2022119829A (ja) 2016-11-08 2022-05-17 自己免疫疾患を処置するためのｉｌ－２変異体

Country Status (15)

Country Link
US (2) US11077172B2 (https=)
EP (1) EP3538548A4 (https=)
JP (2) JP2019532996A (https=)
KR (1) KR20190083656A (https=)
CN (1) CN110167957A (https=)
AU (1) AU2017359172A1 (https=)
CA (1) CA3041334A1 (https=)
CL (1) CL2019001265A1 (https=)
CO (1) CO2019005922A2 (https=)
EA (1) EA201991142A1 (https=)
EC (1) ECSP19041447A (https=)
IL (1) IL266178A (https=)
MX (1) MX2019005400A (https=)
SG (1) SG11201903882VA (https=)
WO (1) WO2018089420A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
KR20250156190A (ko) 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
WO2020007937A1 (en) * 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
BR112021002250A2 (pt) 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
CA3137971A1 (en) * 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN114853874B (zh) * 2019-09-10 2024-05-17 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
IL292803A (en) 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
CA3166009A1 (en) * 2020-01-14 2021-07-22 Synthekine, Inc. Il2 muteins
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
IL301027A (en) 2020-09-04 2023-05-01 Shandong Simcere Biopharmaceutical Co Ltd Mutant AI 2 and its application
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
JP2023548311A (ja) 2020-10-29 2023-11-16 ブリストル－マイヤーズ スクイブ カンパニー 疾患の治療のための融合タンパク質
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
US20240148827A1 (en) * 2021-03-11 2024-05-09 The Methodist Hospital Methods and Compositions for Treatment of Disease
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
EP4323392A4 (en) * 2021-04-16 2025-03-19 Orionis Biosciences, Inc. IL-2-BASED CONSTRUCTS
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054868A1 (en) * 2022-09-07 2024-03-14 Xencor, Inc. An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis
WO2024199458A1 (en) * 2023-03-29 2024-10-03 Wuxi Biologics (Shanghai) Co., Ltd. Il-2 variants with improved stability and compositions thereof
GB202412853D0 (en) 2024-09-02 2024-10-16 Ensocell Ltd Agents and methods directed to disease-associated cells

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
AU627477B2 (en) 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1995008340A1 (en) 1993-09-21 1995-03-30 Amgen Inc. Method for treating psoriasis
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
EP1349873B1 (en) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
WO2003012036A2 (en) 2001-07-27 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
JP2008528621A (ja) 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 腎細胞ガンを処置するための方法
ATE367167T1 (de) 2005-02-07 2007-08-15 Novartis Vaccines & Diagnostic Aufbereitung von aldesleukin zur pharmazeutischen verwendung
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
FR2918770B1 (fr) 2007-07-10 2009-09-11 Essilor Int Afficheur destine a etre integre a une paire de lunettes.
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN102174111B (zh) 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
BR112013023151A2 (pt) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2014094898A (ja) 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN103193887B (zh) 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
PT3172227T (pt) * 2014-07-21 2019-12-06 Delinia Inc Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016057651A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Similar Documents

Publication Publication Date Title
JP2019532996A5 (https=)
JP2020501550A5 (https=)
US12280118B2 (en) IL-2 variant
TW202120548A (zh) 特異性結合mage-a的抗原結合蛋白
EP3202415B1 (en) Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
EP3227342B2 (en) Proteinaceous heterodimer and use thereof
CN100404673C (zh) 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
DK2548574T3 (en) NEW HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
EP3498840A1 (en) Anti-lag-3 antibody
JP2019507589A5 (https=)
RU2019121902A (ru) Поливалентные модуляторы регуляторных t-клеток
JP2018501197A5 (https=)
EA202190669A1 (ru) Процесс получения вакцинной композиции
EP2379584A1 (en) Soluble polypeptides for use in treating autoimmune and inflammatory disorders
EP4534107A3 (en) Protein complex by use of a specific site of an immunoglobulin fragment for linkage
JP2017518303A5 (https=)
JP2017527272A5 (https=)
US20160304579A1 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP3368569B1 (en) Polypeptides against il-23
JP2024540275A5 (https=)
CN116583294A (zh) 抗炎细胞因子及其使用方法
US20260116986A1 (en) Epo receptor agonists and antagonists
JP2017538443A5 (https=)
EP3426681B1 (en) Hla-b57 open conformers
JP7485371B2 (ja) 前立腺特異的膜抗原に結合するキメラ抗原受容体